<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121577</article-id><article-id pub-id-type="doi">10.23868/gc121577</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Properties of tissue-engineering polycaprolactone matrices impregnated by VEGF and bFGF growth factors</article-title><trans-title-group xml:lang="ru"><trans-title>Свойства тканеинженерных матриксов из поликапролактона, импрегнированных факторами роста VEGF и bFGF</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sevostyanova</surname><given-names>V. V</given-names></name><name xml:lang="ru"><surname>Севостьянова</surname><given-names>В. В</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Elgudin</surname><given-names>Y. L</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Wnek</surname><given-names>G. E</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Lubysheva</surname><given-names>T.</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Emancipator</surname><given-names>S.</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Golovkin</surname><given-names>A. S</given-names></name><name xml:lang="ru"><surname>Головкин</surname><given-names>А. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Barbarash</surname><given-names>L. S</given-names></name><name xml:lang="ru"><surname>Барбараш</surname><given-names>Л. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute for Complex Problems of Cardiovascular Disease of SB RAMS, Kemerovo</institution></aff><aff><institution xml:lang="ru">НИИ Комплексных проблем сердечно-сосудистых заболеваний СО РАМН, Кемерово</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Case Western Reserve University, Cleveland, USA</institution></aff><aff><institution xml:lang="ru">Западный резервный университет Кейза, Кливленд, США</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2012</year></pub-date><volume>7</volume><issue>4</issue><issue-title xml:lang="en">VOL 7, NO4 (2012)</issue-title><issue-title xml:lang="ru">ТОМ 7, №4 (2012)</issue-title><fpage>62</fpage><lpage>67</lpage><history><date date-type="received" iso-8601-date="2023-01-11"><day>11</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Эко-Вектор</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121577">https://genescells.ru/2313-1829/article/view/121577</self-uri><abstract xml:lang="en"><p>A contemporary approach to small vascular conduits design for bypass surgery is growing them in vivo using tissue-engineered biodegradable polymer scaffolds. The study assessed the possibility to use grafts made by two-phase electrospinning out of polycaprolactone with impregnated VEGF and bFGF. The scaffolds were tested for the alterations in physical, mechanical and biological properties after their impregnation with the growth factors. An increase in polymer graft strength was observed following their impregnation with VEGF and bFGF. ELISA showed a prolonged biomolecule release out of the scaffold within up to 3 weeks. The results of subcutaneous implantation of the scaffolds to Wistar rats demonstrated that the biological activity of VEGF and bFGF is preserved after their release into the surrounding tissues. Thus, the study showed that there is a possibility to use PCL scaffolds with VEGF and bFGF to design small vascular tissue- engineered grafts.</p></abstract><trans-abstract xml:lang="ru"><p>Современный подход в создании сосудистых кондуитов малого диаметра для применения в шунтирующих операциях заключается в их «выращивании» in vivo с использованием тканеинженерных биодеградируемых полимерных матриксов. В работе оценивается возможность использования графтов, созданных методом двухфазного электроспиннинга из поликапролактона с включением в их состав VEGF и bFGF. Матриксы оценивали на изменение физикомеханических и биологических свойств, после введения в полимер ростовых факторов. Было обнаружено увеличение прочности полимерных матриксов, после их импрегнации VEGF и bFGF. Пролонгированный выход биомолекул из материала в сроки до трех недель был продемонстрирован с помощью иммуноферментного анализа. Результаты подкожной имплантации изучаемых матриксов крысам популяции Wistar подтвердили сохранение биологической активности VEGF и bFGF после их выхода в окружающие ткани. Таким образом, исследование показало возможность использования PCL матриксов с VEGF и bFGF для создания сосудистых тканеинженерных графтов малого диаметра.</p></trans-abstract><kwd-group xml:lang="en"><kwd>VEGF</kwd><kwd>bFGF</kwd><kwd>tissue engineering</kwd><kwd>electrospinning</kwd><kwd>polycaprolactone</kwd><kwd>VEGF</kwd><kwd>bFGF</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>тканевая инженерия</kwd><kwd>электроспиннинг</kwd><kwd>поликапролактон</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Taylor L.M., Edwards J.M., Porter J.M. Present status of reversed vein bypass grafting: five-year results of modern series. J. Vasc. Surg. 1990; 11: 193-205.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Бокерия Л.А., Беришвили И.И., Солнышков Л.Э. и др. Повторные операции у больных ишемической болезнью сердца - современное состояние проблемы. Бюллетень НЦССХ им. Бакулева РАМН. 2009; 10(3): 5-27.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cooper K., Chun I., Colter D., inventors; Ethicon Inc., assignee. Tissue engineered blood vessels. US patent 0,275,129. 2009 Nov 5.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Tillman B., Yazdani S., Lee S. et al. The in vivo stability of electrospun polycaprolactone-collagen scaffolds in vascular reconstruction. Biomaterials 2009; 30: 583-8.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Schantz J.T., Chim H., Whiteman M. Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Eng. 2007; 13(11): 2615-24.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Kim K., Luu Y., Chang C. et al. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-coglycolide)-based electrospun nanofibrous scaffolds. J. Controll. Release. 2004; (98): 47-56.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Verreck G., Chun I., Rosenblatt J. et al. Incorporation of drugs in an amorphous state into electrospun nanofibers composed of a water- insoluble, nonbiodegradable polymer. J. Controll. Release. 2003; 92: 349-60.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Sokolsky-Papkov M., Agashi K., Olaye A. et al. Polymer carriers for drug delivery in tissue engineering. Advanced Drug Delivery Reviews. 2007; (59): 187-206.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Hakkarainen M. Aliphatic Polyesters: Abiotic and biotic degradation and degradation products. Advances in Polymer Science. 2002; 157: 113-8.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Sahoo R., Sahoo S., Sahoo S. et al. Synthesis and characterization of polycaprolactone - gelatin nanocomposites for control release anticancer drug paclitaxel. Euro. J. Sci. Res. 2011; 48(3): 527-37.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zhu X., Eng M., Tabata Y. et al. Delivery of basic fibroblast growth factor from gelatin microsphere scaffold for the growth of human umbilical vein endothelial cells. Tissue Engineering: Part A. 2008; 14(12): 1939-47.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Thevenot P., Nair A., Shen J. et al. The effect of incorporation of SDF-1a into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 2010; 31(19): 3997-4008.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sharon J.L., Puleo D.A. Immobilization of glycoproteains, such as VEGF, on biodegradable substrates. Acta Biomater. 2008; 4(4): 1016-23.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sun Q., Chen R., Shen Y. et al. Sustained vascular endothelial growth factor delivery enhances angiogenesis and perfusion in ischemic hind limb. Pharm. Res. 2005; 22(7): 1110-16.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Guan J., Stankus J., Wagner W. Biodegradable elastomeric scaffolds with basic fibroblast growth factor release. J. Controll. Release. 2007; 120(1-2): 70-8.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Layman H., Spiga M., Brooks T. et al. The effect of the controlled release of basic fibroblast growth factor from ionic gelatin- based hydrogels on angiogenesis in a murine critical limb ischemic model. Biomaterials 2007; 28(16): 2646-54.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Wang Y. Liu X.-C., Zhao J. et al. Degradable PLGA scaffolds with basic fibroblast growth factor. Texas Heart Institute Journal 2009; 36(2): 89-97.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Losi P., Briganti E., Magera A. et al. Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Biomaterials 2010; 31(21): 5336-44.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bolgen N., Menceloglu Y.Z., Acatay K. et al. In vitro and in vivo degradation of non-woven materials made of poly(e-caprolactone) nanofibers prepared by electrospinning under different conditions. J. Biomat. Sci. Polym. Edit. 2005; 16(12): 1537-55.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Ramakrishna S., Fujihara K., Teo W. et al. An introduction to electrospinning and nanofibers. Singapore: World Scientific; 2005.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Cui W., Zhou Y., Chang J. Electrospun nanofibrous materials for tissue engineering and drug delivery. Sci. Technol. Adv. Mater. 2010; (11): 1-11</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Zong X., Ran S., Kim K.-S. et al. Structure and morphology changes during in vitro degradation of electrospun poly(glycolide- co-lactide) nanofibre membrane. Biomacromolecules 2003; (4): 416-23.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Smith M. Biologicaly functional scaffolds for tissue engineering and drug delivery, produced through electrostatic processing [dissertation]. Cleveland (OH): Case Western Reserve Univ.; 2010.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Mandriota S.J., Pepper M.S. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J. Cell Sci. 1997; 110: 2293-302.</mixed-citation></ref></ref-list></back></article>
